Last reviewed · How we verify
slow itraconazole tablet
Slow itraconazole tablet is a modified-release formulation of itraconazole that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in fungal cell membranes.
Slow itraconazole tablet is a modified-release formulation of itraconazole that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in fungal cell membranes. Used for Fungal infections (broad-spectrum including aspergillosis, candidiasis, and other systemic mycoses).
At a glance
| Generic name | slow itraconazole tablet |
|---|---|
| Also known as | slow dissolving itraconazole tablet |
| Sponsor | University of Maryland, Baltimore |
| Drug class | Triazole antifungal |
| Target | Fungal cytochrome P450 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Itraconazole is a triazole antifungal that selectively targets fungal sterol synthesis by inhibiting the demethylation of lanosterol to ergosterol. The slow/modified-release formulation extends drug exposure and improves bioavailability compared to standard itraconazole formulations, allowing for more consistent antifungal activity. This mechanism is effective against a broad spectrum of fungi including Aspergillus, Candida, and other clinically important pathogens.
Approved indications
- Fungal infections (broad-spectrum including aspergillosis, candidiasis, and other systemic mycoses)
Common side effects
- Nausea
- Headache
- Diarrhea
- Rash
- Hepatotoxicity
Key clinical trials
- A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients (PHASE1)
- Itraconazole Oral Absorption (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- slow itraconazole tablet CI brief — competitive landscape report
- slow itraconazole tablet updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI